Clinical Trial Update: Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions [Phase 1]

View source ↗

Summary

A Phase 1 FDA-sponsored study evaluating cannabidiol's effects on liver enzymes and potential drug interactions has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Drug-induced Liver Injury

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: Food and Drug Administration (FDA) | Conditions: Cannabidiol, Drug Induced Liver Injury | Phase 1 | Status: COMPLETED | Results posted: 2025-07-31